Clinical Trial

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The study will assess whether changes in total choline concentration \[tCho\] during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with HER2 negative breast cancer (HNBC) appropriate for NAC, and compare these findings with dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The objective is to assess the predictive value of changes in the concentration and spatial extent of tCho within the tumor during NAC.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-06-13; most recent amendment 2025-05-20.
Status change: Recruiting → Active, Not Recruiting 2025-05-20
Trial Details
NCT Number NCT03568448
Lead Sponsor New Mexico Cancer Research Alliance
Conditions HER2 Negative Breast Cancer
Enrollment 30 participants
Start Date 2018-04-16
Primary Completion 2020-01-22 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-22